Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies (1) - PowerPoint PPT Presentation

Loading...

PPT – Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies (1) PowerPoint presentation | free to download - id: 79b7fd-YmRhM



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies (1)

Description:

GBI Research, the leading business intelligence provider, has released its latest research, “Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies”, which provides in-depth analysis of four key therapeutic indications within the Asia-Pacific (APAC) solid tumors market - bladder cancer, ovarian cancer, pancreatic cancer and prostate cancer - covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. View full Report With TOC: – PowerPoint PPT presentation

Number of Views:10

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies (1)


1

Solid Tumors Market in Asia Pacific to 2019 - New
Drug Approvals and Anticipated Product Launches
to Trigger a Shift in Treatment Paradigm to
Targeted Therapies

Published By GBI Research
Published January 2013
2
Description


GBI Research, the leading business intelligence
provider, has released its latest research,
Solid Tumors Market in Asia Pacific to 2019 -
New Drug Approvals and Anticipated Product
Launches to Trigger a Shift in Treatment Paradigm
to Targeted Therapies, which provides in-depth
analysis of four key therapeutic indications
within the Asia-Pacific (APAC) solid tumors
market - bladder cancer, ovarian cancer,
pancreatic cancer and prostate cancer - covering
the four countries of Australia, China, India and
Japan. The report provides an estimation of
market size for 2012, along with market forecast
until 2019. It also covers disease epidemiology,
treatment algorithms, treatment patterns,
in-depth analysis of the pipeline, and deal
analysis for these four solid tumor types. The
value of the solid tumors market in the APAC
region amounted to an estimated 1 billion in
2012 and is expected to register a modest
Compound Annual Growth Rate (CAGR) of 12.3 to
reach 2.3 billion in 2019.
3
Description


The key drivers for growth in this market
include new product approvals in ovarian,
pancreatic and prostate cancers expected
launches from the promising ovarian and prostate
cancer pipelines and increased market
penetration due to the anticipated implementation
of social insurance in China. Conversely, the
growth of the market in this region could face
some restricting influences, including the
recent implementation of a price ceiling on
essential drugs in India anticipated pricing
restrictions in China low access and
penetration and price erosion due to generic
competition. Scope The report analyzes
treatment usage patterns, market
characterization, pipeline analysis and key
licensing and co-development deals in the bladder
cancer, ovarian cancer, pancreatic cancer and
prostate cancer in the four APAC markets of
Australia, China, India and Japan. The report
includes - - Disease overview, as well as
treatment algorithms and treatment usage patterns
4
Description

Reasons to buy The report will enhance your
decision-making capability by allowing you to -
- Align your product portfolio to the markets
with high growth potential - Develop market entry
and expansion strategies by identifying the
potential regions and therapeutic segments poised
for strong growth - Devise a more effectively
tailored country strategy through the
understanding of key drivers and barriers in the
solid tumors market - Develop key strategic
initiatives based upon an understanding of key
focus areas and leading companies - Accelerate
and strengthen your market position by
identifying key companies for mergers,
acquisitions and strategic partnerships
5
Table Of Content

  • 1 Table of Contents
  • 2 Introduction
  • 3 Marketed Products
  • 3.1 Product Profile
  • 3.1.1 Spiriva - Beranger Ingelheim
    Pharmaceuticals, Pfizer Inc.
  • 3.1.2 Advair Diskus - GlaxoSmithKline
  • 3.1.3 Symbicort - AstraZeneca (Co-promotion with
    Astellas Pharma Inc)
  • 3.1.4 Combivent- Boehringer Ingelheim
  • 3.1.5 Foradil - Novartis (Co-marketed by Novartis
    and Schering Corporation)
  • 3.1.6 Arcapta/Onbrez Breezhaler - Novartis
  • 3.1.7 Daliresp - Nycomed
  • 3.1.8 Seebri Breezhaler - Novartis
  • 3.1.9 Striverdi Respimat - Boehringer Ingelheim
  • 3.1.10 Relvar/Breo - GlaxoSmithKline/Theravance

6
Table Of Content

  • 3.1.11 Heat Map - Marketed Products Overview
  • 4 COPD Pipeline
  • 5 Market Forecast to 2019
  • 7 Appendix
  • View full report with TOC
  • http//www.reportsandintelligence.com/solid-tumors
    -in-asia-pacific-to-2019-new-drug-approvals-and-an
    ticipated-product-launches-to-trigger-a-shift-in-t
    reatment-paradigm-to-targeted-therapies-market/tab
    le-of-contents
  • View Sample of report at
  • http//www.reportsandintelligence.com/enquire-abou
    t-report/132399

7

FOR MORE DETAILS
Visit us at
http//www.reportsandintelligence.com/solid-tumors
-in-asia-pacific-to-2019-new-drug-approvals-and-an
ticipated-product-launches-to-trigger-a-shift-in-t
reatment-paradigm-to-targeted-therapies-market
Stay With Us
TELEPHONE Direct 1 (617) 674-4143 Toll Free
1 (855) 711-1555E-MAIL sales_at_reportsandintellig
ence.com
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
About PowerShow.com